Article 1 to 10 out of 22 concerning BioInvent International AB
ThromboGenics and BioInvent Win "Licensing Deal of the Year” at the Scrip Awards 2009(20 Nov 2009) Strategic partnership with Roche for novel anti-cancer antibody TB-403 (anti-PIGF) recognised in award ThromboGenics NV and BioInvent International announce that they won "Licensing Deal of the Year” at the Scrip Awards 2009. The award recognises the major partnership deal that ThromboGenics and BioInvent signed with Roche for their novel ...
BioInvent Appoints Head of Preclinical Research(26 May 2009) BioInvent International AB announced that it has appointed Björn Frendeus to Vice President Preclinical Research.Björn Frendeus, 36 years, will head BioInvent’s research projects up to identification of potential product candidates for further ...
ThromboGenics and BioInvent Start Phase II Trial of TB-402, an Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis (24 Feb 2009) Trial to assess the benefits of partial Factor VIII inhibition in patients undergoing knee replacement surgery ThromboGenics NV and co-development partner BioInvent International announce that the first patient has been enrolled in the Phase II trial with their long-acting anticoagulant TB-402 for the prophylaxis of Deep Vein Thrombosis (DVT) following ...
Top
